.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 5,980,867

« Back to Dashboard

Claims for Patent: 5,980,867

Title: Flunisolide aerosol formulations
Abstract:Pharmaceutical aerosol formulations comprising flunisolide, ethanol, and a propellant selected from the group consisting of 1,1,1,2-tetrafluoroethane, 1,1,1,2,3,3,3-heptafluoropropane, and a mixture thereof.
Inventor(s): Tzou; Tsi-Zong (Lake Elmo, MN), Schultz; Robert K. (Edina, MN), Ross; Danna L. (Pine Springs, MN)
Assignee: 3M Innovative Prperties Company (St. Paul, MN)
Application Number:09/110,796
Patent Claims: 1. An aerosol formulation comprising: about 0.1 percent to about 0.9 percent by weight of flunisolide in solution; a propellant comprising a hydrofluorocarbon selected from the group consisting of 1,1,1,2-tetrafluoroethane, 1,1,1,2,3,3,3,-heptafluoropropane, and a mixture thereof, and about 3 percent to about 30 percent by weight ethanol in an amount effective to solubilize the flunisolide in the formulation.

2. An aerosol formulation according to claim 1, wherein the propellant comprises 1,1,1,2-tetrafluoroethane.

3. An aerosol formulation according to claim 1, wherein the propellant comprises 1,1,1,2,3,3,3-heptafluoropropane.

4. An aerosol formulation according to claim 1, wherein the propellant comprises a mixture of 1,1,1,2-tetrafluoroethane and 1,1,1,2,3,3,3-heptafluoropropane.

5. An aerosol formulation according to claim 1, characterized in that it is substantially free of chlorofluorocarbon propellants.

6. An aerosol formulation according to claim 1 further comprising about 0.005 percent to about 1 percent by weight water.

7. An aerosol formulation according to claim 1 further comprising about 0.001 percent to about 0.1 percent by weight sorbitan trioleate.

8. An aerosol formulation according to claim 1 further comprising about 0.001 percent to about 0.2 percent by weight cetylpyridinium chloride.

9. An aerosol formulation according to claim 1 further comprising a flavoring agent.

10. An aerosol formulation according to claim 1 further comprising about 0.3 percent by weight menthol.

11. An aerosol formulation according to claim 1 comprising from about 0.2 percent to about 0.5 by weight flunisolide, from about 10 to about 20 percent by weight ethanol, and 1,1,1,2,3,3,3-heptafluoropropane.

12. An aerosol formulation according to claim 11 comprising from about 0.2 percent to about 0.5 percent by weight flunisolide, from about 10 to about 20 percent by weight ethanol and from about 0.001 percent to about 0.005 percent by weight sorbitan trioleate.

13. An aerosol formulation according to claim 1 comprising from about 0.2 percent to about 0.5 by weight flunisolide, from about 10 to about 20 percent by weight ethanol, and 1,1,1,2-tetrafluoroethane.

14. An aerosol formulation according to claim 13 comprising from about 0.2 percent to about 0.5 percent by weight flunisolide, from about 10 to about 20 percent by weight ethanol and from about 0.001 percent to about 0.005 percent by weight sorbitan trioleate.

15. A method of treating bronchial asthma comprising administering via inhalation an amount of a formulation according to claim 1 sufficient to treat bronchial asthma.

16. A metered dose inhaler comprising: (i) an aerosol canister defining a formulation chamber; and (ii) a formulation according to claim 1, wherein said formulation is contained within said formulation chamber.

17. An inhaler according to claim 16, wherein the formulation chamber is coated with a resin that is inert to flunisolide.

18. An inhaler according to claim 17, wherein the resin is an epoxy resin.

19. An inhaler according to claim 16, wherein the aerosol canister is glass .
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc